All subjects received placebo solution (vehicle diluent) during a 2-week run-in period; selected subjects were then randomized 1:1 to receive either placebo or PL9643 topical ophthalmic solution bilaterally 3 times daily for 12 weeks. Co-primary endpoints were changes in inferior corneal ...